Multi Cancer Early Detection (MCED) Test Market Size & Share 2026-2035

Multi Cancer Early Detection (MCED) Test Market Size

The global multi cancer early detection (MCED) test market was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.5 billion in 2026 to USD 5.3 billion by 2035, expanding at a CAGR of 14.8%, according to the latest report published by Global Market Insights Inc. The steady growth of the market is driven by the increasing prevalence of cancer, advancements in data analytics and artificial intelligence (AI) utilized in cancer screening, and a high cancer detection rate coupled with a growing demand for effective cancer tools, among other factors.

The major players in the global market are GRAIL, EXACT SCIENCES CORPORATION, Guardant Health, Guangzhou AnchorDx Medical, and Genecast Biotechnology. These companies maintain their competitive position through ongoing product innovation, global market presence, collaboration with healthcare facilities, and substantial investment in the market.

The multi cancer early detection test market grew from USD 700 million in 2022 to USD 1.1 billion in 2024, registering a historical growth rate of 18.7%. The significant increase in the number of cases of cancer is the main factor that is driving the growth of the multi-cancer early detection (MCED) test market. For instance, as per the data reported by the World Health Organization (WHO), the number of new cancer cases per year is projected to reach around 35 million by 2050 from 20 million cases in 2022, a rise of over 77%. Due to the increasing patient base, there is an urgent need to provide effective screening methods to determine if a person has multiple types of cancers at their earliest and most treatable phases.

Additionally, as the number of cancers continues to increase due to rising age, changing lifestyles, environmental exposure, and inherited genetics, healthcare providers focus on developing better ways for diagnosing cancers early so that patients receive better care. The MCED test offers a minimally invasive method of detecting many types of cancers using a single blood sample and is therefore witnessing an increasing demand for this test from healthcare providers, payors, and patients for use in mass cancer screening programs.

Technological advancements in data analytics and artificial intelligence (AI) significantly enhance the accuracy, speed, and efficiency of cancer screening procedures, hence driving growth within the multi-cancer early detection (MCED) testing market. AI algorithms can analyze very large volumes of genomic, epigenomic, proteomic, and clinical data to detect subtle patterns associated with cancer that might not be easily identified by traditional methods. The use of machine learning models also improves MCEDs’ ability to predict the presence of cancer in addition to determining the tissue of origin from the same blood sample. All of these benefits reduce the number of diagnostic errors, allow for individualized risk assessment, and provide increased confidence among healthcare providers who utilize MCED technologies, among other benefits.

A multi-cancer early detection (MCED) test is a blood-based screening test designed to detect signals associated with multiple types of cancer simultaneously, often before symptoms appear. MCED tests typically analyze biomarkers such as circulating tumor DNA (ctDNA), DNA methylation patterns, proteins, or other cancer-related molecular signatures present in a blood sample. These tests aim to complement existing cancer screening methods by enabling earlier detection across a broad range of cancers.

Multi Cancer Early Detection (MCED) Test Market Trends

Growing adoption of liquid biopsy technologies, expansion of precision medicine approaches, integration of artificial intelligence and advanced analytics, and rising focus on preventive healthcare and population screening are among the key trends shaping the market growth in an upward trajectory.

• The growing trend toward non-invasive or minimal invasion in diagnostics will continue to increase the use of liquid biopsy products for MCED testing. Use of blood-based samples may enable the detection of cancer-related biomarkers, provide patients with greater comfort and adherence, and allow healthcare professionals to diagnose multiple types of cancer earlier compared to standard methods.
• In addition, the increase in emphasis on personalized medicine has spurred advancements in the development of new cancer screening methods that are designed specifically for an individual's unique risk profile. MCED tests are increasingly being incorporated into precision medicine strategies, allowing for targeted monitoring, risk assessment, and early intervention for individuals at increased risk of developing cancer in the future.
• Further, artificial intelligence and machine learning technology are enhancing the MCED testing process as they improve the analysis of biomarkers, detection of cancer signals, and determination of tissue origin. The advancement of data analytics capabilities will increase test accuracy, decrease uncertainty in diagnoses, and support more reliable clinical decision-making that will improve confidence among healthcare professionals.

Multi Cancer Early Detection (MCED) Test Market Analysis

Based on type, the market is segmented into gene panel, LDT, and others; and liquid biopsy. The gene panel, LDT, and others segment was valued at USD 1.2 billion in 2025 and held a dominant market share of around 91.9%.

• The MCED market consists of gene panels, LDTs, and other methods used to identify genetic changes in various types of cancer. The majority of these tests use one or more genomic regions, methylation signatures, or other molecular markers related to the development of cancer. They are flexible enough for laboratories to modify testing based on the clinical and demographic needs of their patients.
• Additionally, continuous improvements in sequencing technologies, bioinformatics tools, and the discovery of biomarkers have enabled the analytical performance of these tests to be enhanced.
• Further, increasingly aggressive demand for individualized cancer screening and risk assessment is helping support continued use of these tests in research facilities, diagnostic laboratories, and specialized healthcare settings.
• The liquid biopsy segment accounted for USD 106.3 million in 2025 and is projected to grow at a steady CAGR over the forecast period. It is a key element within the MCED market because of their minimally invasive nature and ability to detect cancer in a small volume of blood from patients.
• Liquid biopsies utilize the analysis of biomarkers in the bloodstream, such as cell-free DNA, circulating tumor DNA, proteins, or specific molecular signatures that suggest a potential presence of tumors.
• Moreover, they provide significant advantages over traditional forms of tumor detection, including improved patient convenience, ease of implementation, and scalability in terms of application for screening.

Based on biomarker class, the multi cancer early detection (MCED) test market is segmented into cfDNA methylation analysis, somatic mutation/ctDNA, protein biomarker-based, multi-analyte/multi-omics, and fragmentomics and CNV. The cfDNA methylation analysis segment was valued at USD 549.8 million in 2025.

• One of the most common methods for detecting cancer in circulating cell-free DNA (cfDNA), as part of the multi-cancer early detection (MCED) approach, is to analyze DNA methylation profiles of cfDNA that has been released into the bloodstream as a result of cancer cell death.
• Since abnormal DNA methylation changes are some of the first alterations to occur in the development of a tumor, developing a blood test based on cfDNA methylation may provide a significant opportunity to identify multiple different cancers before symptoms are present.
• Additionally, recent developments in sequencing technology and computational analysis are improving the accuracy and reliability of cfDNA methylation-based cancer detection solutions.
• The somatic mutation/ctDNA segment accounted for a 20.5% of multi cancer early detection (MCED) test market share in 2025 and is projected to grow at a robust CAGR over the forecast period. Metastatic cancer's mutated genetic material can be identified through blood testing using tumor-derived somatic mutations or circulating tumor DNA (ctDNA).
• These mutations provide strong evidence that the individual has cancer and allow for early detection of the disease.
• Further, ctDNA analysis supports the detection of a broad range of malignancies and plays an increasingly important role in cancer screening, monitoring, and treatment selection.
• The protein biomarker-based segment accounted for USD 210.8 million in 2025. Multicancer Early Detection (MCED) assays based on protein biomarkers evaluate the diagnostic accuracy of proteins found in the blood related to cancer detection and progression.
• Moreover, biomarkers provide valuable biological characteristics related to tumor characteristics and the development of diseases associated with tumors.
• Furthermore, protein evaluations can be performed in conjunction with genomic and epigenomic evaluations to improve the sensitivity of the overall test. The continuing research on new protein signatures and multiplex testing platforms will improve the potential to use protein biomarkers in MCED programs.

Based on end use, the multi cancer early detection test market is segmented into hospitals, diagnostic laboratories, and other end users. The hospitals segment held a leading market share of 48.7% in 2025.

• Hospitals are a critical end-use segment for MCED tests, as they play an essential role in cancer screening and diagnosis and the overall management of patients with cancer. Therefore, large healthcare organizations are increasingly evaluating MCED assay technology as part of their oncology and preventive care program initiatives.
• In addition, the availability of multidisciplinary clinical teams enables effective interpretation of complex test results and facilitates follow-up diagnostic procedures when necessary.
• With a greater focus on providing early diagnosis of associated cancers, improved patient outcomes to create long-term health benefits, and moving toward a value-based healthcare system, hospitals are increasingly interested in assessing new and innovative cancer screening options.
• Additionally, with the continued expansion of the overall clinical evidence supporting the use of MCED testing in a hospital environment, it will support the industry growth.
• The diagnostic laboratories segment accounted for USD 472.1 million in 2025 and is projected to grow at a steady CAGR over the forecast period. Diagnostic laboratories are among the primary users of MCED tests because they possess the technical infrastructure required for advanced molecular testing and genomic analysis. These facilities play a critical role in sample processing, biomarker analysis, and result interpretation.
• Further, increasing demand for high-throughput testing, coupled with advancements in sequencing technologies and automation, is enhancing laboratory capabilities in multi-cancer detection.
• Moreover, the continued expansion of precision diagnostics and personalized medicine is expected to strengthen the importance of diagnostic laboratories within the MCED ecosystem.

North America Multi Cancer Early Detection (MCED) Test Market

The North America region accounted for 42.3% of the market in 2025. The market in North America is experiencing robust expansion, driven by the region’s advanced healthcare infrastructure and technological advancements.

• The U.S. multi cancer early detection (MCED) test market was valued at USD 285.4 million and USD 349 million in 2022 and 2023, respectively. In 2025 the market size increased to USD 522.8 million from USD 428.6 million in 2024.
• The region is witnessing growing adoption of liquid biopsy technologies and molecular testing solutions, supported by expanding clinical research activities and increasing acceptance of blood-based cancer screening approaches among healthcare providers.
• The presence of leading biotechnology and diagnostic companies is accelerating innovation in biomarker discovery, artificial intelligence-driven data analysis, and test development.
• Favorable reimbursement discussions, ongoing clinical validation efforts, and strong collaboration between healthcare systems, research institutions, and industry participants continue to support market expansion across the region.

Europe Multi Cancer Early Detection (MCED) Test Market

Europe multi cancer early detection (MCED) test industry accounted for USD 350.3 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• The market in Europe is growing steadily due to increasing emphasis on early cancer diagnosis, preventive healthcare initiatives, and advancements in genomic medicine.
• Healthcare systems across the region are focusing on reducing cancer-related mortality through earlier detection and improved patient management strategies.
• In addition, growing investments in molecular diagnostics, next-generation sequencing technologies, and translational cancer research are supporting the adoption of innovative screening solutions.
• Furthermore, collaborative research projects involving hospitals, academic institutions, and biotechnology companies are accelerating clinical evidence generation for MCED technologies.

Asia Pacific Multi Cancer Early Detection (MCED) Test Market

The Asia Pacific region is projected to show a lucrative growth of about 16.1% during the forecast period.

• Asia Pacific is emerging as a rapidly growing market for MCED tests due to its large population base, rising cancer incidence, and improving healthcare infrastructure. The growing burden of cancer is encouraging governments and healthcare organizations to explore innovative screening approaches that can support earlier diagnosis and improve treatment outcomes.
• Increasing investments in biotechnology, genomics, and precision medicine are fostering the development and adoption of advanced cancer detection technologies throughout the region.
• In addition, expanding access to healthcare services, rising healthcare expenditure, and growing awareness of preventive screening are further supporting market growth. Countries across the region are also strengthening research capabilities and encouraging collaborations between domestic and international diagnostic developers.

Latin America Multi Cancer Early Detection (MCED) Test Market

Brazil is experiencing significant growth in the multi cancer early detection (MCED) test industry.

• Rising cancer prevalence across the region is creating demand for innovative screening technologies that can enable earlier identification of disease and support more effective treatment planning.
• Investments in healthcare infrastructure and diagnostic laboratory capabilities are contributing to the adoption of advanced molecular testing solutions.
• Growing awareness among healthcare professionals regarding liquid biopsy and precision medicine is also supporting interest in MCED technologies.
• Further, increasing partnerships between healthcare providers, diagnostic companies, and research organizations are expected to enhance the availability and utilization of multi-cancer detection tests throughout the region.

Middle East and Africa Multi Cancer Early Detection (MCED) Test Market

• The Middle East and Africa MCED test industry is experiencing gradual growth, supported by increasing investments in healthcare infrastructure and expanding efforts to improve cancer diagnosis and treatment outcomes.
• Governments and healthcare organizations are placing greater emphasis on early disease detection as part of broader public health improvement initiatives. Growing awareness of cancer screening, rising healthcare expenditure, and increasing adoption of advanced diagnostic technologies are contributing to market development.
• Several countries are investing in precision medicine programs, genomic research, and modern laboratory facilities to strengthen oncology care capabilities. In addition, collaborations with international healthcare and biotechnology organizations are helping expand access to innovative diagnostic solutions.

Multi Cancer Early Detection (MCED) Test Market Share

The multi cancer early detection test industry is characterized by intense innovation and competition among biotechnology companies, molecular diagnostics developers, and precision medicine firms seeking to establish leadership in early cancer detection. Competition is primarily focused on improving test sensitivity, specificity, tissue-of-origin identification capabilities, and overall clinical utility. Companies are investing significantly in biomarker discovery, next-generation sequencing technologies, artificial intelligence-driven analytics, and large-scale clinical validation studies to differentiate their offerings.

Leading participants are pursuing extensive research and development initiatives to strengthen their proprietary platforms and expand cancer detection capabilities across multiple cancer types. Strategic collaborations with hospitals, academic institutions, diagnostic laboratories, and healthcare providers have become a key competitive strategy for accelerating technology development, generating clinical evidence, and expanding commercial reach.

Additionally, the market is also witnessing increasing efforts to secure regulatory approvals and reimbursement support, as these factors are critical for large-scale adoption and commercialization. Companies with strong clinical datasets and validated testing platforms are better positioned to gain physician trust and improve market penetration.

Further, regional players are emerging with specialized genomic and methylation-based technologies, increasing competition across both developed and emerging healthcare markets. As the industry evolves, competition is expected to shift beyond detection accuracy toward affordability, accessibility, data integration, and seamless incorporation into routine preventive healthcare and population screening programs. Overall, technological innovation, clinical validation, strategic partnerships, and commercialization capabilities remain the key determinants of competitive success in the market.

Multi Cancer Early Detection (MCED) Test Market Companies

Few of the prominent players operating in the multi cancer early detection (MCED) test industry include:

• AnPac Bio-Medical Science
• Burning Rock Biotech
• EarlyDiagnostics
• Elypta
• EXACT SCIENCES CORPORATION
• Freenome Holdings
• Genecast Biotechnology
• GRAIL
• Guangzhou AnchorDx Medical
• GUARDANT HEALTH
• Harbinger Health
• Micronoma
• SeekIn
• Singlera Genomics

• EXACT SCIENCES CORPORATION

Exact Sciences emphasizes strengthening its cancer detection portfolio through continuous biomarker research, product innovation, strategic collaborations, clinical validation studies, and expanding access to non-invasive screening solutions.

• Guangzhou AnchorDx Medical

Guangzhou AnchorDx Medical focuses on developing proprietary genomic and methylation-based technologies, enhancing early cancer detection capabilities, expanding regional market presence, and building partnerships with clinical laboratories and hospitals.

Multi Cancer Early Detection (MCED) Test Industry News:

• In September 2025, Exact Sciences Corp. announced the launch of the Cancerguard test, a new multi-cancer early detection (MCED) blood test available as a laboratory-developed test (LDT) in the U.S. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers. This development may improve the company's presence in the industry in the coming years.
• In June 2024, Illumina, Inc. officially completed the spin-off of GRAIL, making it an independent, publicly traded company. Illumina now holds a 14.5% minority stake in GRAIL and continues to support it with sequencing technology and services. The divestiture allows GRAIL to pursue its mission independently, focusing on regulatory approvals, payer coverage, and broader commercialization.

The multi cancer early detection (MCED) test market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Gene panel, LDT, and others
• Liquid biopsy

Market, By Biomarker Class

• cfDNA methylation analysis
• Somatic mutation / ctDNA
• Protein biomarker-based
• Multi-analyte / multi-omics
• Fragmentomics and CNV

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE